Equity Details
Price & Market Data
Price: $1.85
Daily Change: +$0.0202 / 1.09%
Daily Range: $1.79 - $1.90
Market Cap: $336,764,416
Daily Volume: 5,213,513
Performance Metrics
1 Week: -4.10%
1 Month: -64.04%
3 Months: -71.67%
6 Months: -55.79%
1 Year: -6.97%
YTD: -65.18%
About Compass Therapeutics, Inc. (CMPX)
Get current market data for Compass Therapeutics, Inc. (CMPX). Price: 1.85, daily change: +$0.0202 / 1.09%. Market cap: 336,764,416. Performance YTD, 1-week, 3-month.
Company Details
Employees: 39
Sector: Health technology
Industry: Pharmaceuticals: major
Country: United States
Details
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, develops antibody-based therapeutics for the treatment of various human diseases in the United States. The company's lead product candidate, tovecimig, is a bispecific antibody that targets delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGF-A), which are critical to angiogenesis and tumor vascularization. It also develops CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells; CTX-8371, a bispecific inhibitor that targets programmed cell death protein-1 (PD-1) and ligand PD-L1 checkpoint inhibitor antibodies; and CTX-10726, a bispecific antibody that targets PD-1 and VEFG-A. The company was founded in 2014 and is headquartered in Boston, Massachusetts.